Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Castle Bio Prices IPO at $16 per Share

Castle Bio Prices IPO at $16 per Share

Jul 25, 2019
|
staff reporter

NEW YORK — Skin cancer test developer Castle Biosciences said today that it has priced its planned initial public offering at $16 a share, the top end of the previously disclosed range.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Robots for the Lab

Researchers have developed a robotic lab assistant, the Verge reports.

Ruling Awaited

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

To Find Where It Came From

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

Science Presents Atlas of Aberrant Cells in Lung Condition, More

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.

Jul
14
Featured Webinar

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

Sponsored by
Agilent

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
22
Featured Webinar

Advances in Genetic Testing for IVF Research: PGT-A, PGT-M, and Carrier Screening

Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Molecular Diagnostics

  1. Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

  2. Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis

  3. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

  4. FDA Grants EUA for UCSF, Broad Institute, BioSewoom Coronavirus Tests

  5. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.